In8Bio (INAB) Common Equity (2020 - 2026)
In8Bio (INAB) posted Common Equity of $22.8 million for Q1 2026, down 17.33% sequentially from $27.6 million in Q4 2025, and up 64.16% YoY from $13.9 million in Q1 2025.
In8Bio (INAB) Common Equity (2020 - 2026) Analysis & Trends
In8Bio has reported Common Equity for 7 years, with the latest figure at $22.8 million in Q1 2026.
- Quarterly Common Equity rose 64.16% year-over-year to $22.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.8 million (up 64.16% YoY) and the FY2025 annual result came in at $27.6 million, up 90.34% from the prior year.
- Common Equity slipped to $22.8 million in Q1 2026 per INAB's latest filing, from $27.6 million in the prior quarter.
- Over five years, Common Equity peaked at $32.8 million in Q1 2022 and troughed at $8.6 million in Q3 2024.
- A 5-year average of $20.0 million and a median of $17.8 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity jumped 276.71% in 2022, then tumbled 51.64% in 2024.
- Over 5 years, Common Equity stood at $22.7 million in 2022, then increased by 9.7% to $24.9 million in 2023, then slumped by 41.94% to $14.5 million in 2024, then jumped by 90.34% to $27.6 million in 2025, then retreated by 17.33% to $22.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $22.8 million, $27.6 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.79 Bn |
| 10 | In8Bio | 23.75 Mn | 23.75 Mn | - | 18.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.36 Mn |
| Mar 31, 2026 | 22.78 Mn |
| Dec 31, 2025 | 27.56 Mn |
| Sep 30, 2025 | 13.19 Mn |
| Jun 30, 2025 | 15.24 Mn |
| Mar 31, 2025 | 13.88 Mn |
| Dec 31, 2024 | 14.48 Mn |
| Sep 30, 2024 | 8.59 Mn |
| Jun 30, 2024 | 13.62 Mn |
| Mar 31, 2024 | 17.53 Mn |
| Dec 31, 2023 | 24.94 Mn |
| Sep 30, 2023 | 17.76 Mn |
| Jun 30, 2023 | 21.80 Mn |
| Mar 31, 2023 | 16.79 Mn |
| Dec 31, 2022 | 22.73 Mn |
| Sep 30, 2022 | 29.56 Mn |
| Jun 30, 2022 | 26.57 Mn |
| Mar 31, 2022 | 32.84 Mn |
| Dec 31, 2021 | -38.18 Mn |
| Sep 30, 2021 | 43.04 Mn |